EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
(NASDAQ: EYPT) Delayed: 3.85 -0.14 (3.51%)
Previous Close $3.99    52 Week High $ 
Open $3.95    52 Week Low $ 
Day High $4.06    P/E N/A 
Day Low $3.77    EPS $ 
Volume 7,264,450